Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 204

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019

Open access
Price, Christina C., Altice, Frederick L., Shyr, Yu, Koff, Alan, Pischel, Lauren, Goshua, George, Azar, Marwan M., Mcmanus, Dayna, Chen, Sheau-Chiann, Gleeson, Shana E., Britto, Clemente J., Azmy, Veronica, Kaman, Kelsey, Gaston, David C., Davis, Matthew, Burrello, Trisha, Harris, Zachary, Villanueva, Merceditas S., Aoun-Barakat, Lydia, Kang, Insoo, Seropian, Stuart, Chupp, Geoffrey, Bucala, Richard, Kaminski, Naftali, Lee, Alfred I., LoRusso, Patricia Mucci, Topal, Jeffrey E., Dela Cruz, Charles, Malinis, Maricar·2020·Chest

Abstract

Background Tocilizumab, an IL-6 receptor antagonist, can be used to treat cytokine release syndrome (CRS), with observed improvements in a coronavirus disease 2019 (COVID-19) case series. Research Question The goal of this study was to determine if tocilizumab benefits patients hospitalized with COVID-19. Study Design and Methods This observational study of consecutive COVID-19 patients hospitalized between March 10, 2020, and March 31, 2020, and followed up through April 21, 2020, was conducted by chart review. Patients were treated with tocilizumab using an algorithm that targeted CRS. Survival and mechanical ventilation (MV) outcomes were reported for 14 days and stratified according to disease severity designated at admission (severe, ≥ 3 L supplemental oxygen to maintain oxygen saturation > 93%). For tocilizumab-treated patients, pre/post analyses of clinical response, biomarkers, and safety outcomes were assessed. Post hoc survival analyses were conducted for race/ethnicity. Results Among the 239 patients, median age was 64 years; 36% and 19% were black and Hispanic, respectively. Hospital census increased exponentially, yet MV census did not. Severe disease was associated with lower survival (78% vs 93%; P < .001), greater proportion requiring MV (44% vs 5%; P < .001), and longer median MV days (5.5 vs 1.0; P = .003). Tocilizumab-treated patients (n = 153 [64%]) comprised 90% of those with severe disease; 44% of patients with nonsevere disease received tocilizumab for evolving CRS. Tocilizumab-treated patients with severe disease had higher admission levels of high-sensitivity C-reactive protein (120 vs 71 mg/L; P < .001) and received tocilizumab sooner (2 vs 3 days; P < .001), but their survival was similar to that of patients with nonsevere disease (83% vs 91%; P = .11). For tocilizumab-treated patients requiring MV, survival was 75% (95% CI, 64-89). Following tocilizumab treatment, few adverse events occurred, and oxygenation and inflammatory biomarkers (eg, high-sensitivity C-reactive protein, IL-6) improved; however, D-dimer and soluble IL-2 receptor (also termed CD25) levels increased significantly. Survival in black and Hispanic patients, after controlling for age, was significantly higher than in white patients (log-rank test, P = .002). Interpretation A treatment algorithm that included tocilizumab to target CRS may influence MV and survival outcomes. In tocilizumab-treated patients, oxygenation and inflammatory biomarkers improved, with higher than expected survival. Randomized trials must confirm these findings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.chest.2020.06.006

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 21

  1. Sanders, 2020, pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review, JAMA, 10.1001/jama.2020.6019 · DOI · Paper page
  2. Wang, 2020, C reactive protein level may predict the risk of COVID-19 aggravation, Open Forum Infect Dis, 7, ofaa153, 10.1093/ofid/ofaa153 · DOI · Paper page
  3. Wu, 2020, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern Med, 10.1001/jamainternmed.2020.0994 · DOI · Paper page
  4. Yang, 2020, The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis, J Infect
  5. Mehta, 2020, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, 395, 1033, 10.1016/S0140-6736(20)30628-0 · DOI · Paper page
  6. Michot, 2020, Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report, Ann Oncol, 10.1016/j.annonc.2020.03.300 · DOI · Paper page
  7. Zhang, 2020, The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality, Int J Antimicrob Agents, 55, 105954, 10.1016/j.ijantimicag.2020.105954 · DOI · Paper page
  8. Bersanelli, 2020, Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors, Immunotherapy, 10.2217/imt-2020-0067 · DOI · Paper page
  9. Xu, 2020, Effective treatment of severe COVID-19 patients with tocilizumab, Proc Natl Acad Sci U S A, 10.1073/pnas.2005615117 · DOI · Paper page
  10. Navarro, 2014, Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums, Semin Arthritis Rheum, 43, 458, 10.1016/j.semarthrit.2013.08.001 · DOI
  11. Chen, 2019, Management of cytokine release syndrome related to CAR-T cell therapy, Front Med, 13, 610, 10.1007/s11684-019-0714-8 · DOI
  12. Luo, 2020, Tocilizumab treatment in COVID-19: a single center experience, J Med Virol, 10.1002/jmv.25801 · DOI · Paper page
  13. Sciascia, 2020, Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19, Clin Exp Rheumatol
  14. Weissman, 2020, Locally informed simulation to predict hospital capacity needs during the COVID-19 pandemic, Ann Intern Med, 10.7326/L20-1062 · doi:10.7326/l20-1062
  15. Wells, 2020, Projecting the demand for ventilators at the peak of the COVID-19 outbreak in the USA, Lancet Infect Dis, 10.1016/S1473-3099(20)30315-7 · DOI
  16. Weiss, 2020, Clinical course and mortality risk of severe COVID-19, Lancet, 395, 1014, 10.1016/S0140-6736(20)30633-4 · DOI · Paper page
  17. Yang, 2020, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med, 10.1016/S2213-2600(20)30079-5 · DOI · Paper page
  18. Bhatraju, 2020, COVID-19 in critically ill patients in the Seattle region—case series, N Engl J Med, 10.1056/NEJMoa2004500 · DOI · Paper page
  19. Bikdeli, 2020, COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up, J Am Coll Cardiol, 10.1016/j.jacc.2020.04.031 · DOI · Paper page
  20. Rubin, 1990, The soluble interleukin-2 receptor: biology, function, and clinical application, Ann Intern Med, 113, 619, 10.7326/0003-4819-113-8-619 · DOI · Paper page
  21. Feng, 2020, COVID-19 with different severity: a multi-center study of clinical features, Am J Respir Crit Care Med, 10.1164/rccm.202002-0445OC · DOI · Paper page

Cited by

See all 204

Metadata

Authors
Price, C. C., Altice, F. L., Shyr, Y., Koff, A., Pischel, L., Goshua, G., Azar, M. M., Mcmanus, D., Chen, S.-C., Gleeson, S. E., Britto, C. J., Azmy, V., Kaman, K., Gaston, D. C., Davis, M., Burrello, T., Harris, Z., Villanueva, M. S., Aoun-Barakat, L., Kang, I., Seropian, S., Chupp, G., Bucala, R., Kaminski, N., Lee, A. I., LoRusso, P. M., Topal, J. E., Dela Cruz, C., & Malinis, M.
Venue
Chest
Publisher
Elsevier BV
Published
2020-10
Volume
158
Issue
4
Pages
1397-1408
ISSN
0012-3692 (ISSN-L)
OpenAlex
W3089952857
Cited by
204
References
6
FWCI
5.76
Type
journal article
Language
en
Open access
bronze
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019. https://app.cochat.ai/papers/10.1016/j.chest.2020.06.006
The paper
Price, C. C., Altice, F. L., Shyr, Y., Koff, A., Pischel, L., Goshua, G., Azar, M. M., Mcmanus, D., Chen, S.-C., Gleeson, S. E., Britto, C. J., Azmy, V., Kaman, K., Gaston, D. C., Davis, M., Burrello, T., Harris, Z., Villanueva, M. S., Aoun-Barakat, L., . . . Malinis, M. (2020). Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019. Chest. https://doi.org/10.1016/j.chest.2020.06.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.